Resverlogix Corp. (OTC:RVXCF)
Industry: Healthcare

OFF LIST - 761 consecutive market days: OFF LIST as of 05/28/2013 Through 11/14/2016

Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Current Quote*
Last: $2.380
Change: -0.020
Book: $Unk
Volume: 21,934

As Of: 11/20 16:07 ET
*Quotes delayed by 20min.

Graphs for RVXCF


3 Month Graph


6 Month Graph


1 Year Graph